Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Non-Current Debt (2023 - 2024)

Iovance Biotherapeutics (IOVA) has disclosed Non-Current Debt for 3 consecutive years, with $1.0 million as the latest value for Q4 2024.

  • On a quarterly basis, Non-Current Debt changed 0.0% to $1.0 million in Q4 2024 year-over-year; TTM through Dec 2024 was $1.0 million, a 0.0% change, with the full-year FY2024 number at $1.0 million, changed 0.0% from a year prior.
  • Non-Current Debt was $1.0 million for Q4 2024 at Iovance Biotherapeutics, roughly flat from $1.0 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $1.0 million in Q1 2023 to a low of $1.0 million in Q1 2023.